Review on natural killer/T‐cell lymphoma
Hematological Oncology · 2023-04 · 41 (2) · 221-229
DOI: 10.1002/hon.2944 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematological Oncology, online erschienen am 09.12.2021. Verfasst von Xiaohua He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen Uni…. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Lymphoma, Extranodal NK-T-Cell. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Guangzhou Science and Technology Project, National Science and Technology Major Project, Sun Yat-sen University Cancer Center Clinical Research 308 Program.
Abstract (Originalsprache)
Extranodal natural killer (NK)/T‐cell lymphoma (ENKTL) is strongly associated with Epstein–Barr virus (EBV) and has a high prevalence in Asian and in Central and South America. About 85% of ENKTLs derive from NK cells and 15% from T‐cells. Various factors have been implicated in the development of ENKTL. Molecular pathogenesis of NK/T‐cell lymphomas include mutations of genes, involving in the Janus Kinase/signal transducer and activator of transcription pathway, RNA helicase family, epigenetic regulation, and tumor suppression. The relationship between ENKTL and human leukocyte antigen has been demonstrated. Radiotherapy plays a key role in the first‐line treatment of early‐stage. In stage III/IV diseases, non‐anthracycline‐regimens‐containing L‐asparaginase are recommended. Although clinical remission after L‐asparaginase‐based combination therapy has been achieved in the majority of patients with advanced‐stage or relapsed/refractory extranodal NK/T‐cell lymphoma‐nasal type, the long‐term overall survival is still poor. Recently, immunotherapy and new therapeutic targets have gained much attention. In this article, we discuss the pathogenesis, diagnosis, prognostic models and management options of ENKTL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
ORCID-Profile: Zhiming Li
Förderung
- Guangzhou Science and Technology Project
- National Science and Technology Major Project
- Sun Yat-sen University Cancer Center Clinical Research 308 Program
- National Natural Science Foundation of China
Zitieren
APA
He, X., Gao, Y., Li, Z., & Huang, H. (2023). Review on natural killer/T‐cell lymphoma. Hematological Oncology, 41(2), 221-229. https://doi.org/10.1002/hon.2944
Vancouver
He X, Gao Y, Li Z, Huang H. Review on natural killer/T‐cell lymphoma. Hematological Oncology. 2023;41(2):221-229. doi:10.1002/hon.2944
BibTeX
@article{He2023,
author = {He, Xiaohua and Gao, Yan and Li, Zhiming and Huang, Huiqiang},
title = {Review on natural killer/T‐cell lymphoma},
journal = {Hematological Oncology},
year = {2023},
volume = {41},
number = {2},
pages = {221--229},
doi = {10.1002/hon.2944}
}
EUVIMED